Here, we detail a unique case of a child exhibiting diffuse spinal nerve root hypertrophy in the context of epidermal nevus syndrome driven by molecularly confirmed <i>KRAS G12D</i> mosaicism, treated with the MEK 1/2 inhibitor selumetinib. Here, KRAS is linked to epidermal nevus syndrome.